Head-to-head comparison
| Property | BPC-157 | MGF |
|---|---|---|
| Category | Recovery | Muscle & Growth |
| Legal Status | Reclassification Pending | Research Only |
| Primary Route | subcutaneous | intramuscular |
| Half-life | ~4 hours (estimated) | Native MGF: minutes; PEG-MGF: several days (pegylation dramatically extends duration) |
| Mol. Weight | 1,419.53 Da | 2,867.2 Da |
| Side Effects | Nausea (rare), Dizziness, Headache | Injection site pain or swelling, Hypoglycemia (theoretical, shared with IGF-1 family), Local tissue growth at injection site (with repeated IM injection) |
Key differences
- Mechanism: BPC-157 activates the FAK-paxillin pathway for broad tissue repair and modulates nitric oxide; MGF activates muscle satellite cells for localized muscle fiber repair via the IGF-1 signaling cascade.
- Tissue specificity: BPC-157 works on tendons, ligaments, gut, and multiple tissue types; MGF is specifically targeted at skeletal muscle repair and growth.
- Origin: BPC-157 is a 15-amino-acid fragment of human gastric juice; MGF is a splice variant of IGF-1 (insulin-like growth factor 1) produced in response to mechanical muscle damage.
- Administration: BPC-157 is used subcutaneously, intramuscularly, or orally; MGF is typically injected intramuscularly at the site of muscle damage for localized effect.
- Half-life: BPC-157 has an estimated half-life of approximately 4 hours; MGF has a very short half-life of minutes (PEG-MGF extends this significantly).
- Evidence base: BPC-157 has over 100 preclinical studies across multiple tissue types; MGF has a smaller body of research focused primarily on skeletal muscle biology.
- Use context: BPC-157 is used for general injury recovery (tendons, joints, GI); MGF is used specifically for muscle injury and hypertrophy support.
The verdict
BPC-157 and MGF are complementary rather than competing peptides. BPC-157 is the broader-spectrum repair peptide suitable for tendon, ligament, gut, and general tissue healing. MGF is specifically targeted at skeletal muscle, activating satellite cells for muscle fiber repair and growth. For general injury recovery, BPC-157 has the wider evidence base. For targeted muscle repair, MGF addresses a more specific niche. Some protocols combine both for comprehensive recovery.
Frequently asked questions
They work through different mechanisms and target different aspects of tissue repair, making them potentially complementary. BPC-157 addresses broad tissue healing while MGF specifically targets muscle satellite cell activation. No clinical studies have evaluated this combination.
MGF is more specifically targeted at skeletal muscle repair through satellite cell activation. BPC-157 has broader tissue repair evidence including some muscle-related studies. For isolated muscle tears or strains, MGF is more precisely targeted; for injuries involving tendons or connective tissue alongside muscle, BPC-157 may be more relevant.
PEG-MGF is a PEGylated (polyethylene glycol-modified) version of MGF that dramatically extends its half-life from minutes to hours. Standard MGF degrades very rapidly, making PEG-MGF the more practical form for systemic use. Local injection of standard MGF can partially circumvent the half-life limitation.
BPC-157 primarily promotes tissue repair rather than muscle growth specifically. MGF is a splice variant of IGF-1 that directly activates muscle satellite cells for hypertrophy. BPC-157 supports the healing environment, while MGF more directly promotes muscle fiber regeneration.
BPC-157 has a larger total body of research with over 100 preclinical studies across multiple tissue types. MGF research is more focused on skeletal muscle biology and growth factor signaling. Neither has completed human clinical trials for therapeutic applications.